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Abstract
Despite major efforts to reduce atherosclerotic cardiovascular disease (ASCVD) burden with conventional risk factor
control, significant residual risk remains. Recent evidence on non-traditional determinants of cardiometabolic health has
advanced our understanding of lifestyle–disease interactions. Chronic exposure to environmental stressors like poor
diet quality, sedentarism, ambient air pollution and noise, sleep deprivation and psychosocial stress affect numerous
traditional and non-traditional intermediary pathways related to ASCVD. These include body composition, cardio-
respiratory fitness, muscle strength and functionality and the intestinal microbiome, which are increasingly recognized
as major determinants of cardiovascular health. Evidence points to partially overlapping mechanisms, including effects on
inflammatory and nutrient sensing pathways, endocrine signalling, autonomic function and autophagy. Of particular
relevance is the potential of low-risk lifestyle factors to impact on plaque vulnerability through altered adipose tissue and
skeletal muscle phenotype and secretome. Collectively, low-risk lifestyle factors cause a set of phenotypic adaptations
shifting tissue cross-talk from a proinflammatory milieu conducive for high-risk atherosclerosis to an anti-atherogenic
milieu. The ketone body ß-hydroxybutyrate, through inhibition of the NLRP-3 inflammasome, is likely to be an inter-
mediary for many of these observed benefits. Adhering to low-risk lifestyle factors adds to the prognostic value of
optimal risk factor management, and benefit occurs even when the impact on conventional risk markers is discouragingly
minimal or not present. The aims of this review are (a) to discuss novel lifestyle risk factors and their underlying
biochemical principles and (b) to provide new perspectives on potentially more feasible recommendations to improve
long-term adherence to low-risk lifestyle factors.
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Introduction
The global burden of obesity, type 2 diabetes mellitus
(T2DM) and metabolic syndrome (MetS) is continu-
ously increasing and may be the largest yet-known
non-infectious pandemic, subsequently leading to an
enormous increase of atherosclerotic cardiovascular
diseases (ASCVDs).1 ASCVD heavily depends on
modiﬁable factors,2 but despite major eﬀorts to
manage conventional risk factors, signiﬁcant residual
risk, which varies across studies and methods of statis-
tical analysis, remains.3
To date, lifestyle guidance has failed to substantially
impact the burden from the twin epidemics of meta-
bolic disease and ASCVD. Rising healthcare costs high-
light the need for new strategies that have the potential
to improve long-term adherence.
The aims of this review are (a) to discuss new life-
style risk factors, their underlying biochemical prin-
ciples, and public heath interventions that have the
potential to reduce the burden from ASCVD and (b)
to provide novel perspectives on potentially more feas-
ible recommendations to improve long-term adherence
to low-risk lifestyle risk factors.
Of particular relevance in cardiovascular prevention
is the eﬀect of lifestyle risk factors on plaque phenotype
and vulnerability, as depicted in Figure 1 and as dis-
cussed below.
Recommendations regarding lifestyle
risk factors
Diet
Malnutrition, in terms of quantity and quality, has
become the leading risk factor for disability and death
worldwide.2 During the past decades, dietary guidance
has focused on calorie- and nutrient-based approaches,
with one of the major targets being restriction of diet-
ary (in particular, saturated) fat.4 However, there is no
evidence that this has substantially reduced the cardio-
metabolic disease burden. A major limitation of the
calorie- and nutrient-centric model is that it disregards
the complex and weight-independent eﬀects of food
matrix and dietary patterns on metabolic and hormonal
responses related to satiety and other intermediary
pathways relevant to cardiovascular and overall
health, such as the intestinal microbiome.4–7 Another
layer of complexity is added by concerns about the use
of error-prone methodology in nutritional epidemi-
ology to inform dietary advice. Memory-based assess-
ment methods such as food frequency questionnaires
can produce physiologically implausible data (i.e.
incompatible with survival).8,9 Therefore, this review
focuses on evidence from randomized controlled trials
(RCTs) on surrogate markers for cardiometabolic
health and clinical endpoints. The resulting conceptual
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Figure 1. Lifestyle and high-risk atherosclerosis. Lifestyle risk factors influence plaque composition by modulating traditional and
novel pathways associated with cardiovascular risk. Red colour indicates initiation of high-risk atherosclerosis, green colour indicates
inhibition of high-risk atherosclerosis.
FA: fatty acids; T2DM: type 2 diabetes mellitus.
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frameworks might help inform dietary recommenda-
tions in clinical practice.
Food- versus nutrient-based recommendations. First and
foremost, judging a food’s health eﬀects by its individ-
ual nutrients without considering food matrix does not
confer meaningful information.2 Evidence from RCTs
on clinical endpoints provides robust support for the
superiority of food-based recommendations without spe-
ciﬁc guidance regarding calories, as opposed to nutrient-
and calorie-based recommendations.7 Outcome evidence
supporting this concept came from the two largest dietary
intervention trials with cardiovascular endpoints. The
PREDIMED trial demonstrated that adhering to a cal-
orie-unrestricted Mediterranean-style dietary pattern sup-
plemented with four tablespoons of extra virgin olive oil
or 30 g mixed nuts per day over 4.9 years in high-risk
patients reduced inﬂammation10 and the incidence of
major cardiovascular events by 31% and 28%, respect-
ively.11 Of note, these eﬀects were independent of body
weight and lipid-lowering.11 This stands in stark contrast
to the Women’s Health Initiative (WHI), the largest diet-
ary RCT ever performed. In the WHI, a fat-restricted
dietary pattern involving speciﬁc guidance on caloric
intake failed to signiﬁcantly reduce cardiovascular end-
points after eight years despite a substantial achieved
reduction in total fat intake (37.8% to 28.8%).12
Body composition versus body weight. Second, the eﬀects of
diet on health seem to be more closely related to body
composition than to body weight and total fat mass per
se, suggesting that body mass index (BMI) can be an
inadequate measure for assessing the eﬀects of diet on
health.13 In the CENTRAL-MRI trial, a Mediterranean
low carbohydrate dietary pattern was superior to a low
fat diet in mobilizing atherogenic and diabetogenic fat
depots in liver, pancreas and pericardium; changes in
lipid traits related to MetS (triglycerides and triglycer-
ide/high-density lipoprotein cholesterol ratio) correlated
with reductions in visceral/hepatic fat, but not with
BMI.14 This supports the notion that visceral, intra-
organ and subcutaneous adipose tissue depots have dis-
tinct associations with cardiometabolic health,15,16 and
selective mobilization of visceral/ectopic fat is a funda-
mental mechanism underlying improved metabolic func-
tion. Overall, the combination of anthropometric
and laboratory markers indicative of visceral adiposity
(e.g. waist circumference and triglycerides) appears
more indicative of adipose tissue distribution and pheno-
type than BMI.17 Hypertriglyceridemic waist, a visceral
adiposity marker combining elevated waist circumfer-
ence (90 cm) and elevated fasting plasma triglycerides
(2mmol/L), is indicative of the high-risk meta-
bolic phenotype18 and/or high risk atherosclerosis.15
Waist-to-height-ratio is another inexpensive metric to
better inform cardiovascular risk stratiﬁcation than
BMI and/or waist circumference alone; the suggested
general cutoﬀ being 0.5.16,19
Carbohydrate restriction/nutritional ketosis. Third, insulin
resistance alters metabolic responses to dietary cues.
Although of immense and yet to be fully elucidated
complexity on a cellular and molecular level, insulin
resistance clinically manifests itself as an intolerance
to dietary carbohydrate; glycogen synthesis is impaired
and dietary carbohydrate is diverted at increasing rates
into hepatic de novo lipogenesis.20 Conceptually, this is
of clinical relevance for dietary recommendations in
MetS and T2DM and provides a reasonable explan-
ation for evidence supporting use of dietary carbohy-
drate restriction and (intermittent) caloric restriction in
the dyslipidaemic, insulin resistant phenotype, where
favourable metabolic changes are observed in the
absence of weight loss.21–23
It is worth noting that carbohydrate restriction is not a
new concept but was successfully applied to treat diabetes
mellitus prior to the discovery of insulin.24 With the dis-
covery of insulin in 1923, which allowed for acute symp-
tom control in diabetes even with high carbohydrate diets,
this potent therapy has been largely forgotten.
With the delineation of the cellular and metabolic
responses to carbohydrate restriction, these dietary
regimens have recently regained scientiﬁc interest. In
the insulin resistant phenotype, very low carbohydrate
dietary patterns resulting in nutritional ketosis reduce
broad, systemic inﬂammation and most biomarkers of
ASCVD risk.25 Mechanistically, reduced inﬂammation
has been linked to the ketone body ß-hydroxybutyrate
(BHB),26,27 which is elevated in the state of nutritional
ketosis and, in addition to its role in metabolism, acts
as a signalling molecule.28 BHB blocks an innate
immune sensor, the NLRP3 inﬂammasome, with down-
stream eﬀects resulting in reduced levels of interleukin 1
beta (IL-1b).27 IL-1b and the NLRP3 inﬂammasome
are crucial mediators conferring cardiovascular
risk,29,30 and inhibition of IL-1b eﬀectively reduced car-
diovascular events in the CANTOS trial.31
Furthermore, BHB is an endogenous inhibitor of
class 1 histone deacetylases (HDACs) and thus aﬀects
gene expression via chromatin modiﬁcations.32 HDACs
regulate numerous pathways implicated in longevity
and cardiometabolic disease, including autophagy and
insulin-like growth factor (IGF) signalling. HDAC1
inhibition by BHB provides an example of the close
link between metabolic status/diet and epigenetic gene
regulation.28,32 Other eﬀects of BHB relevant to cardio-
vascular aging include attenuated vascular aging33 and
the promotion of a healthy microbiome.34
Lechner et al. 3
(Intermittent) caloric restriction. Caloric restriction is an
umbrella term summarizing a set of dietary interven-
tions involving either chronically or periodically
reduced energy intake without malnutrition.35 Caloric
restriction has consistently been found to extend
healthy life span across a variety of species, yet the
major limitation in humans is long-term sustainability
for the vast majority. It is thus encouraging that inter-
mittent fasting regimens evoke similar cellular and
metabolic adaptations to chronic caloric restriction.
Time-restricted food intake has been linked to cardio-
metabolic health in animal models36 and humans.22
Intermittent states of negative energy balance activate
a set of adaptations where metabolism switches from
lipid synthesis and fat storage to mobilization of fat as
free fatty acids and fatty acid-derived ketones. This has
been linked to improvement in surrogate markers for
cardiometabolic health (e.g. weight loss) and beneﬁcial
eﬀects on body composition such as mobilization of vis-
ceral fat and retention of lean mass.22,37 Further adapta-
tions include increased circulating ketone and decreased
inﬂammatory cytokine-, fatty acid-, amino acid-, glucose-
and insulin concentrations, which translates to amelio-
rated insulin sensitivity and lipoprotein metabolism.22,37
In people with insulin resistance, metabolic outcomes
appear more favourable upon consumption of the daily
dietary allotment in the ﬁrst half of the day rather than
the same caloric intake divided into six meals throughout
the day.38 Furthermore, in a strictly controlled feeding
trial in men with prediabetes, those who consumed their
meals in a 6-h time window in the morning experienced a
greater amelioration of metabolic markers than those on
a control schedule (12-h time window) within ﬁve weeks,
independent of body weight.39 Another study comparing
two isocaloric weight-loss interventions showed greater
improvement of metabolic markers in the group consum-
ing a bigger breakfast and a smaller dinner than vice
versa.40 Overall, the evidence supports the notion that
both the amount of time spent eating during each day35
and the time at which food is consumed relative to the
circadian rhythm (chrono-nutrition)41 modulate the
eﬀects of diet on cardiometabolic health. Importantly,
no safety signals such as electrolyte imbalance, nausea
and vomiting, hyperuricemia and others have been
reported in intermittent fasting regimens.37
Dietary patterns. Collectively, for maintaining cardiovas-
cular and overall health, strong evidence and broad
consensus speak to minimizing consumption of added
sugars and reﬁned grains and avoiding industrial trans-
fatty acids, while replacing them with plant- and
animal-based whole foods.2
In the insulin resistant phenotype, an overwhelming
body of scientiﬁc literature has documented the super-
iority of low carbohydrate dietary patterns for glycaemic
and weight control in T2DM.21,42–44 It is therefore not
surprising that the recently published Consensus Report
of the American Diabetes Association and the European
Association for the Study of Diabetes endorsed low
carbohydrate diets (<26% of total energy) as one strat-
egy to manage hyperglycemia and hyperinsulinaemia in
T2DM.45
The so called ‘Mediterranean dietary pattern’ sup-
plemented by extra virgin olive oil and nuts is the most
established dietary pattern with regard to reducing car-
diovascular endpoints11 and lowering apolipoprotein
B.46 However, it should be mentioned that (a) the
Mediterranean diet is highly heterogeneous, (b) it has
mostly been tested in a Mediterranean country, and (c)
it might not be a feasible option for large parts of the
population globally.
Emerging evidence from animal and human studies
suggests the utility of time restricted feeding regimens in
cardiometabolic disease. Interestingly, ketogenic diets
seem to phenocopy some of the biochemical character-
istics of fasting, including several pathways that are
associated with longevity and cardiovascular health.
Nutritional ketosis has been linked to an inhibition of
major signalling pathways associated with growth
(insulin, IGF-1 and mTOR), activation of AMP-acti-
vated protein kinase (AMPK), and an induction of
antioxidant genes. BHB is likely to be an intermediary
for many of the beneﬁts observed with nutritional keto-
sis and caloric restriction.26,27
Marine n-3 fatty acids
Mechanisms of action. The marine n-3 fatty acids eicosa-
pentaenoic acid (EPA) and docosahexaenoic acid (DHA)
are essential to cell membrane health in all tissues, mod-
ulating a variety of humoral (Figure 2(a)), metabolic
(Figure 2(b) to (d)) and structural parameters (Figure
2(e) to (g)) related to cardiometabolic risk – in part due
to their anti-inﬂammatory properties.47,48 Of particular
relevance to ASCVD is the beneﬁcial eﬀect of EPA on
oxidative stress/inﬂammation, endothelial function and
plaque phenotype, and lipid metabolism, which may
delay the onset of atherosclerosis and the clinical sequelae
associated with acute plaque rupture (reviewed in Ganda
et al.49). Relevant mechanisms include inhibition of
inﬂammation-related pathways and reduced leukocyte-
endothelial adhesive interactions including reduced circu-
lating plasma levels of IL-6, tumour necrosis factor a,50
monocyte chemoattractant protein-1 and asymmetric
dimethylarginine.51 Furthermore, n-3 fatty acids are pre-
cursors of specialized pro-resolving mediators, such as
resolvins, protectins and maresins,47 which support reso-
lution of inﬂammation and plaque stability.52
The most consistent cardiovascular beneﬁt of DHA
and EPA is protection from sudden cardiac death.48,53
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This has been linked, in part, to their membrane stabi-
lizing and antiarrhythmic properties in the setting of
ischaemia-induced ventricular ﬁbrillation.54
The incorporation of EPA/DHA into cellular mem-
branes associated with arterial plaque has been shown
to have local inﬂammatory resolving eﬀects, including
reductions in IL-6, matrix metalloproteinases and lipo-
protein-associated phospholipase A2 (Lp-PLA2).49
This has been linked to increased plaque stability and
protection from the clinical sequelae associated with
acute plaque destabilization, occlusion of arterial
blood ﬂow and tissue infarction.49,54,55
With regard to hepatic lipid metabolism (Figure 2(b)),
n-3 fatty acids have been shown to downregulate hepatic
genes involved in hepatic de novo lipogenesis, thus
depleting the hepatic pool of triglycerides.48 High intakes
of DHA/EPA ameliorate atherogenic dyslipidaemia and
particle distribution48,56 and have furthermore been
linked to reductions in ApoB46 and ApoCIII.56
Trial evidence. Short-term supplementation trials with
high doses of both EPA57 and DHA58 aﬀected surrogate
markers relevant to ASCVD. EPA at 4, but not 2, g/day
reduced oxidized-low density lipoprotein, Lp-PLA2
and high-sensitivity C-reactive protein (hsCRP) levels
compared with placebo.57 DHA at 3 g/day has been
shown to reduce levels of IL-6, hsCRP and granulocyte
monocyte-colony stimulating factor and to increase the
anti-inﬂammatory matrix-metalloproteinase-2 in hyper-
triglyceridaemic men after three months.58
However, despite biological plausibility and favour-
able short-term eﬀects on surrogate markers of cardio-
metabolic health, results of large trials assessing EPA
and/or DHA supplementation with cardiovascular end-
points have been mixed. In ASCEND, 1 g n-3 fatty
acids/day did not reduce adverse vascular events in
individuals with T2DM.59 Conversely, in REDUCE-
IT, treatment of patients at elevated cardiovascular
risk (elevated triglyceride levels and previous cardiovas-
cular event or T2DM) with 4 g of EPA/day resulted in a
25% relative risk reduction (number needed to treat,
21) of the primary composite end point of cardiovascu-
lar death, non-fatal myocardial infarction, non-fatal
stroke, coronary revascularization or unstable angina
Effects of marine n-3 FA, as demonstrated in mechanistic studies in humans
Effects on metabolic dysfunction
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Effects on structural dysfunction
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Figure 2. Marine n-3 fatty acids and mechanisms related to cardiovascular risk. Mechanistic studies in humans have demonstrated
that the marine n-3 fatty acids eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA) reduce serum triglycerides, shift low-
density lipoprotein subfractions and reduce ApoB (b), favourably change body composition (b, c), have direct effects on cardiac
electrophysiology and autonomic function, and mitigate adverse remodelling of the left ventricle after myocardial infarction (e),
improve endothelial function and lower systolic and diastolic blood pressure (f), and increase plaque stability (g) – in part due to their
inflammatory resolving properties (a). Furthermore, EPA/DHA improve cognitive function across different age groups, including in the
elderly and in children (d).
FA: fatty acids; TAG: triglycerides; Apo: apolipoprotein; LDL: low-density lipoprotein; CRP: C-reactive protein; IL-6: interleukin 6;
TNF-a: tumour necrosis factor a; Lp-PLA2: lipoprotein-associated phospholipase A2.
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compared with the placebo group.60 It is noteworthy
that these results were achieved on top of statin ther-
apy, suggesting additive value of EPA.60
One explanation for these diverging results might be
the large variabilities in baseline levels and in bioavail-
ability of EPA and/or DHA, which combine to produce
substantial overlaps of n-3 levels in active treatment
and placebo groups during supplementation trials.61
Group discrimination can be augmented by using a
high dose, as in REDUCE-IT or JELIS,62 or by recruit-
ing participants with low baseline levels, as in GISSI-
HF,63 with the consequence of positive trial results.
Additionally, it may be prudent to monitor erythrocyte
levels of EPA and/or DHA during supplementation
trials and in clinical practice, because rather than with
group assignment or intake, clinical events correlate
with tissue levels of EPA and/or DHA.61
Collectively, cumulative evidence from controlled
studies on risk factors and recent clinical trials with
endpoints, combined with the low risk proﬁle of n-3
polyunsaturated fatty acids, justiﬁes supplementation
as a reasonable option to lower risk of ASCVD in indi-
viduals who do not frequently consume ﬁsh or are at
high risk of ASCVD.7
Physical activity
Physical inactivity and low cardiorespiratory ﬁtness
(CRF) are under-recognized cardiometabolic risk fac-
tors and are strong independent predictors of outcomes
in primary and secondary prevention of ASCVD across
diﬀerent BMI groups.64–67 Encouragingly, high levels
of physical activity and CRF largely neutralize the
adverse eﬀects of adiposity and other traditional car-
diovascular disease risk factors, including the metabolic
syndrome.64 Furthermore, there is clinically relevant
and plausible (although not conclusive) evidence that
a sedentary lifestyle independent of physical activity
and loss of muscle mass, strength and functionality
might independently contribute to ASCVD risk.68–70
Importantly, these metrics can be improved, including
in the elderly population.71,72 Even if started late in life,
physical activity improves functional independence and
reduces mortality, maintaining a strong eﬀect even after
controlling for potential confounders such as smoking,
hypertension, obesity and diabetes.70 This implies
therapeutic potential and underscores the importance
of addressing CRF, muscle strength and functionality,
and sedentary behaviour reduction as independent
therapeutic targets in cardiovascular disease prevention
and management.
Mechanisms of action. Physical activity evokes a complex
systemic network of endo- and paracrine responses
linked to cardiometabolic health. This has been
attributed, in large part, to exercise-induced alterations
in white adipose tissue and skeletal muscle phenotype
and secretome. Muscle and white adipose tissue impact
on inter-organ cross-talk, an eﬀect mediated by adipo-
kines, myokines, and gaseous messengers such as nitric
oxide. Physical activity, particularly resistance training,
aﬀects body composition in a way that promotes an
overall anti-inﬂammatory and anti-atherogenic
milieu.15,29,71 Of particular current interest is skeletal
muscle maintenance as a way of attenuating immunose-
nescence and inﬂammation, a hallmark of chronic, age-
related diseases.73
The eﬀect of physical activity on brown adipose
tissue is less clear and studies have yielded conﬂicting
results.74 One plausible explanation for improved body
composition in overweight/obese individuals with phys-
ical exercise75–77 is the potential for physical activity
to induce adipose tissue browning, an eﬀect that has
been linked to the PGC-1a-dependent myokine irisin
secreted by muscle ﬁbres upon exercise. Browning of
adipose tissue encompasses a phenotypic set of adapta-
tions that results in increased basal metabolic rate and
total energy expenditure.
Further mechanisms of action relevant to cardiovas-
cular health include improved endothelial function,78
preservation of the stable phenotype of pre-existing
atherosclerotic plaque,71 increased autonomic balance,
and downregulation of pathways related to nutrient
sensing, growth signalling and inﬂammation – with
compounding eﬀects.14,71,79,80 The mild antidepressant
eﬀect of physical activity may constitute another inter-
mediary pathway that reduces cardiovascular risk.
Recommendations. Guidelines recommend 150–300 min of
moderate-intensity or 75–150 min of vigorous-intensity
activity weekly for adults, supplemented by two sessions
of muscle-building exercise. Furthermore, the updated
Physical Activity Guidelines for Americans have included
recommendations on sedentary time reduction.81
Moderate-to-vigorous physical activity. The recom-
mended amount of 150 min per week of physical activity
is associated with a 15% decreased risk of coronary
heart disease and a 4.5 year increase in life expectancy.82
Given the problems associated with long-term adherence
to moderate-to-vigorous exercise it is encouraging to
note that even 15 min per day of moderate-intensity
exercise delivers signiﬁcant health beneﬁts and has
been associated with a 14% reduction in all-cause mor-
tality and increased life expectancy of 3.5 years.83
Sedentary behaviour ‘sitting time’. Sedentary time is
ubiquitous and accumulates while commuting, at
school, in the workplace, at home and in leisure con-
texts.84 Objective measurements from accelerometers
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indicate US adults are exposed to an average of 6–8 h
of prolonged sitting time, and adults> 60 years old to
an average of 8.5–9.6 h sedentary time per day – the
metabolic consequences of which are deleterious.68
Epidemiological evidence imply that greater time
spent in sedentary behaviour is associated with all-
cause and cardiovascular morbidity and mortality, sug-
gesting prolonged sitting time as a population-wide,
ubiquitous health risk. While deﬁnitive evidence from
randomized clinical trials in humans is lacking, evi-
dence from preclinical and short-term mechanistic stu-
dies in humans has identiﬁed potential underlying
biological mechanisms,68,81 including decreased insulin
sensitivity and impaired vascular endothelial-dependent
dilation as key antecedents of age-related ASCVD risk.
Encouragingly, these can be reversed by introducing
several short bouts of exercise to uninterrupted sit-
ting,68,81,85 including in the elderly.86
This highlights the importance of working on popu-
lation-wide initiatives to reduce sedentary behaviour.84
This can be implemented by workplace-based interven-
tions that oﬀer activity-permissive workstations by
enabling oﬃce workers to stand, walk or pedal while
doing desk-based tasks and the use of smartphone
applications to interrupt sedentary time.68,81
Overall, exercise training can be an eﬀective and safe
strategy for primary and secondary prevention of
ASCVD across all weight groups.66,71 Combination of
all modalities, endurance/resistance training and seden-
tary time reduction is likely to convey the greatest
cumulative beneﬁt with regard to improved body com-
position, glycaemic control and reduced inﬂammation,
given their activation of diﬀerent physiological signals
and adaptations.78 Although the evidence on the
adverse cardiometabolic eﬀects of time spent in seden-
tary behaviour is less robust, it seems appropriate to
promote ‘Sit less, move more’ as an important public
health recommendation.68,81
Passive exposure to tobacco smoke
While smoking is an acknowledged risk factor for
ASCVD, the detrimental health eﬀects of exposure to
passive smoke are frequently overlooked. Evidence
from studies in humans shows that even brief exposure
to secondhand smoke acutely increases the risk of
acute myocardial infarction (AMI) by 30%.87
Mechanistically, this has been linked to increased plate-
let activity, impaired endothelial function and increased
inﬂammation/oxidative stress.87 Similarly, epidemio-
logical data shows an overall reduction in hospital
admissions for AMI by 17% following smoking bans
in public areas, with the greatest eﬀect in non-smo-
kers.88 Noteworthy, Helena, Montana experienced a
temporary decline in hospital admissions for AMI of
40% within six months after smoke-free legislation –
with admission rates readily returning to baseline
(þ46%) after the ban was suspended.88 On the basis
of available evidence, smoke-free legislation appears
to be a prudent public health action in countries that
have not yet endorsed this.
Alternative modes of nicotine delivery
Electronic nicotine delivery systems (ENDSs) such as
e-cigarettes are increasingly used as potentially less
harmful, alternative modes of nicotine delivery.89
Although results have been mixed, there is evidence
to suggest that smokers switching to ENDS improve
lung function90 and disease symptoms attributable to
asthma and chronic obstructive pulmonary disease.90,91
However, considering the use of ENDS relative to no
use (absolute harm), the best advisory is likely to be
complete abstinence from smoking.
Recreational use of shisha smoking has gained popu-
larity worldwide. This is of concern, given that reported
potential short-term eﬀects on markers of cardiovascu-
lar risk are similar to that of cigarette smoking, includ-
ing increased oxidative stress, platelet dysfunction,
increased blood pressure and heart rate.92,93 Even
more concerning is that one session of waterpipe
tobacco smoking has been shown to elicit larger acute
eﬀects compared with smoking one cigarette.94
Novel lifestyle risk factors
Chronic exposure to (a) environmental stressors like
ambient air pollution and nocturnal and diurnal
noise,95,96 (b) quantitative and qualitative sleep depriv-
ation97–99,100 and (c) psychosocial stress such as loneli-
ness and depression101 are increasingly recognized as
independent risk factors for ASCVD. Evidence points
to partially overlapping disease mechanisms that are
closely related to sympathoadrenergic activation,
chronic upregulation of the hypothalamic–pituitary–
adrenal (HPA) axis and cerebral and systemic chronic
low grade inﬂammation with downstream eﬀects on
endocrine signalling and vascular health.95,96,98,101
Exposure to ambient air pollution. Epidemiological and
toxicological studies have established ambient air pol-
lution as an independent risk factor for ASCVD.95,96
Like exposure to tobacco smoke, ambient particulate
matter (PM), a principal component of air pollutants,
has acute and chronic eﬀects on the cardiovascular
system. The acute toxic eﬀects (seconds–hours) of
exposure to ambient PM are mediated by oxidative
stress, sympathoadrenergic activation, endothelial dys-
function and eﬀects on blood coagulability.95 Of note,
highest risk for acute toxicity occurs within the
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framework of chronic exposure in susceptible patients
characterized by pre-existing ‘vulnerable plaque’, ‘vul-
nerable, proarrhythmic myocardium’ and ‘vulnerable,
prothrombotic circulation’.95 These associations seem
to be strongest for ﬁne particulate air pollutants
(PM< 2.5 mm in diameter (PM2.5)), which are a prin-
cipal component of the combustion-derived nanoparti-
culate in diesel exhaust.95 Public health interventions
targeting reduced burden from ambient PM from air
pollution, particularly PM2.5, have the potential to
reduce morbidity and mortality from ASCVD on a
global scale.102
Exposure to noise. Interestingly, exposure to noise medi-
ates its detrimental eﬀects on cardiovascular health lar-
gely through similar mechanisms as exposure to
ambient air pollution.95,96 For example, exposure to
nocturnal aircraft noise dose-dependently impaired
endothelial function and caused sympathoadrenergic
activation in a cohort of healthy adults free from
ASCVD.103 Mechanistic studies in mice have estab-
lished increased oxidative stress as a causal mechanism
leading to noise-induced endothelial dysfunction.104
Chronic non-resolving inﬂammation thus constitutes a
biologically plausible explanation for the observed
association between chronic noise exposure and
ASCVD, rendering it an important public health
target.103,104
Sleep deprivation. Chronically disrupted circadian
rhythms, through adipose tissue dysfunction and asso-
ciated high-risk metabolic traits, create a milieu condu-
cive for ASCVD.105 A scientiﬁc statement from the
American Heart Association argues in favour of a
sleep duration of 7 h per night for adults.98 This con-
curs with epidemiological evidence that total sleep dur-
ation of 6–8 h per day was associated with the lowest
risk of deaths and major cardiovascular events in a
large cohort of 116,632 people from 21 countries.99
One common cause for sleep fragmentation in adults
is obstructive sleep apnoea syndrome (OSAS), which
speaks for a broader screening for OSAS in cardiovas-
cular prevention.98
Psychosocial stress. One of the principal mechanisms
translating chronic stress into adverse cardiometabolic
outcomes is upregulation of the HPA axis. Chronic ele-
vation of the stress hormone cortisol enhances a set of
phenotypic adaptations which promote an overall pro-
inﬂammatory and pro-atherogenic milieu. This includes
visceral fat accumulation,105 increased peripheral pro-
tein/muscle catabolism, and insulin resistance.101,106 In
line with this, evidence from preclinical studies in rabbit
models of chronic stress shows that exposure to phys-
ical and social stress for eight weeks results in markedly
increased plaque instability, which is manifested by
thinner ﬁbrous caps, larger lipid cores and more inﬂam-
mation, but fewer smooth muscle cells and elastic
ﬁbres.107 This provides a biologically plausible concept
for the observation of increased risk for ASCVD with
chronic stress in humans and might justify the imple-
mentation of stress management programmes such as
mind–body medicine, meditation or physical activity to
prevent and manage ASCVD.101 This is of particular
importance given that psychosocial distress serves as a
barrier to behavioural changes/adoption of a healthy
lifestyle on the one hand and, on the other hand,
stress-induced behavioural compensations (e.g. smok-
ing, increased alcohol consumption or unhealthy food
choices exacerbate novel and traditional risk factors.108
Intestinal microbiome: intermediary pathway for
lifestyle mediated effects on cardiometabolic health?
In recent years, microbiome–health interactions have
been found to play a fundamental role in cardiovascu-
lar health.109 One major link between the intestinal
microbiome and high-risk atherosclerosis is gut dysbio-
sis-related inﬂammation.110 Gut dysbiosis has been
linked to increased mucosal barrier permeability,
which allows the penetration of bacteria and their prod-
ucts – including pathogen-associated molecular pat-
terns, damage-associated molecular patterns and
microbial-associated molecular patterns – into the cir-
culatory system.29 This elicits a systemic, chronic, pro-
inﬂammatory condition and provides a mechanistic
basis for the observed association of ASCVD and a
wide array of non-communicable diseases with gut dys-
biosis.29 Additional mechanisms linking gut micro-
biome and dysbiosis to cardiometabolic risk include
gut microbiota-derived metabolites such as short
chain fatty acids and trimethylamine N-oxide
(TMAO), which are observed in lower and higher con-
centrations, respectively, in non-communicable diseases
(reviewed in Tang et al.109). However, it is less clear
whether dietary sources of TMAO (e.g. l-carnitine in
red meat and lecithin) are the mediating risk factor in
TMAO’s relationship with cardiometabolic risk; the
richest dietary source of preformed TMAO is deep
sea ﬁsh, yet ﬁsh consumption is associated with favour-
able vascular outcomes in a dose-dependent manner.111
Adhering to low-risk lifestyle factors has been linked
to favourable changes in the intestinal microbiome; 112
exercise training,71 (intermittent) caloric restriction29,112
and certain foods, such as nuts,113 rich in soluble ﬁbre,
are associated with increased bacterial gut diversity, a
shift towards health-promoting and butyrate-produ-
cing bacterial species and a protection of the intestinal
barrier. Of note, the ketone body BHB, which is ele-
vated in the state of nutritional ketosis, chemically
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diﬀers from butyrate by only one hydroxyl group. It is
thus tempting to speculate that the observed beneﬁts of
ketogenic diets on inﬂammatory diseases may in part
be attributable to increased intestinal barrier function
and gut health.34
Future directions
Shifting the focus (a) from BMI to body composition
and cardiorespiratory ﬁtness,114 (b) from nutrient- and
calorie-based approaches to food-based, calorie-unrest-
ricted dietary recommendations115 and (c) addressing
exposure to novel lifestyle risk factors through public
health interventions102 might result in more feasible
lifestyle guidance, improve long-term adherence and
ameliorate prognosis115 with combined approaches
achieving cumulative beneﬁt.116
Of emerging interest is the potential health beneﬁt of
‘metabolic switching’ (i.e. intermittent metabolic states
of low cellular energy levels). This can be achieved by
intermittent caloric restriction and physical exercise.
Interestingly, carbohydrate restricted diets resulting in
nutritional ketosis phenocopy the eﬀects of caloric
restriction and/or physical exercise by activating nutri-
ent sensitive pathways linked to low energy metabolic
states (AMPK).117 States of low energy result in
reduced anabolic processes (synthesis, growth and
reproduction) and enhanced maintenance systems,
including increased stress resistance, tissue repair and
recycling of damaged molecules (autophagy).35
Autophagy, also referred to as the body’s innate recy-
cling programme, has been linked to attenuation of
cardiovascular aging through numerous mechanisms,
including reduced inﬂammation/oxidative stress, sup-
pression of mTOR signalling, increased mitochondrial
biogenesis and enhanced endothelial function, among
others.22,118 Collectively, evidence points to similar cel-
lular, molecular and tissue/organ adaptations observed
with exercise, (intermittent) caloric restriction and
carbohydrate restriction27 – the ketone body BHB
through NLRP3 inﬂammasome- and HDAC inhibition
likely being an intermediary for many of the observed
beneﬁts.22,27,28 It is thus tempting to speculate that
BHB, the main circulating ketone body, underlies
many of the long-recognized (cardiovascular) health
beneﬁts of caloric restriction, carbohydrate restriction
and exercise.26,27
Several approaches have been proposed to encour-
age lifestyle modiﬁcation; (a) peer group-based
interventions have proven eﬀective for global cardio-
vascular risk factor modiﬁcation and tobacco cessa-
tion in particular,119 (b) e-health devices,120 (c)
rehabilitation programmes,121 (d) motivational inter-
viewing and (e) the use of positive messages rather
than negative ones.115
Concluding remarks
In conclusion, we posit that cardiovascular disease risk
factors such as visceral adiposity, diabetes, hyperten-
sion and dyslipidaemia might in part be seen as symp-
toms and consequences of high-risk lifestyle risk factors
such as poor diet quality, sedentary behaviour, exposure
to ambient air pollution/noise, sleep deprivation and
psychosocial stress. Adhering to low-risk lifestyle factors
reduces cardiovascular disease risk in a multifactorial
manner, thus signiﬁcantly adding to the prognostic
beneﬁt of conventional risk factor control. Collectively,
low-risk lifestyle factors cause a set of phenotypic adap-
tations that shift tissue cross-talk from a proinﬂamma-
tory milieu conducive for high-risk atherosclerosis, to an
anti-atherogenic milieu. This is a powerful public health
message for clinicians and patients alike.
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